(NASDAQ: VSTM) Verastem's forecast annual revenue growth rate of 160.46% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.98%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.98%.
Verastem's revenue in 2025 is $10,000,000.On average, 3 Wall Street analysts forecast VSTM's revenue for 2025 to be $929,190,465, with the lowest VSTM revenue forecast at $721,482,602, and the highest VSTM revenue forecast at $1,126,457,985. On average, 4 Wall Street analysts forecast VSTM's revenue for 2026 to be $4,939,106,145, with the lowest VSTM revenue forecast at $3,013,961,975, and the highest VSTM revenue forecast at $6,666,433,304.
In 2027, VSTM is forecast to generate $9,851,287,198 in revenue, with the lowest revenue forecast at $6,630,166,852 and the highest revenue forecast at $13,503,209,036.